Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Gacyclidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gacyclidine SCHEMBL397836 | 0.79 | SIGMAR1 (0.57) | MEN1PRCPKMT2ASIGMAR1CHRM3 | |
| Gacyclidine SCHEMBL7190367 | 0.79 | SIGMAR1 (0.57) | MEN1PRCPKMT2ASIGMAR1CHRM3 | |
| Gacyclidine SCHEMBL4465879 | 0.79 | SIGMAR1 (0.57) | MEN1PRCPKMT2ASIGMAR1CHRM3 | |
| Gacyclidine SCHEMBL3457748 | 0.79 | SIGMAR1 (0.57) | MEN1PRCPKMT2ASIGMAR1CHRM3 | |
| Gacyclidine SCHEMBL5398234 | 0.78 | SIGMAR1 (0.56) | MEN1PRCPKMT2ASIGMAR1CHRM3 | |
| Gacyclidine SCHEMBL1662223 | 0.78 | SIGMAR1 (0.56) | MEN1PRCPKMT2ASIGMAR1CHRM3 | |
| SCHEMBL8206550 | 0.68 | MEN1 (0.42) | MEN1PRCPKMT2ASIGMAR1CHRM3 | |
| Felbamate SCHEMBL2946508 | 0.67 | CYP1A2 (1.00) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| Felbamate SCHEMBL34947 | 0.67 | CYP1A2 (1.00) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| Hydrochloric Acid SCHEMBL8205944 | 0.67 | MEN1 (0.41) | MEN1PRCPKMT2ASIGMAR1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007518755-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1708707-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN N-METHYL-D-ASPARTATE (NMDA) RECEPTORS ANTAGONIST | NEUROSEARCH A/S (DK) | 2006-10-11 | — | — | EP | claimed |
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| WO-2005070429-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN N-METHYL-D-ASPARTATE (NMDA) RECEPTORS ANTAGONIST | NEUROSEARCH A/S (DK) | 2005-08-04 | — | — | WO | claimed |
| EP-1708707-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN N-METHYL-D-ASPARTATE (NMDA) RECEPTORS ANTAGONIST | NEUROSEARCH A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| WO-2005070429-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN N-METHYL-D-ASPARTATE (NMDA) RECEPTORS ANTAGONIST | NEUROSEARCH A/S (DK) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | SLC18A2, SLC6A2, SLC6A3 | CYP1A2 685/4885CYP2D6 341/4885PKM 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.